Proguanil and cycloguanil are organic cation transporter and multidrug and toxin extrusion substrates
© The Author(s) 2017
Received: 8 May 2017
Accepted: 11 October 2017
Published: 23 October 2017
Malaria, HIV/AIDS, and tuberculosis endemic areas show considerable geographical overlap, leading to incidence of co-infections. This requires treatment with multiple drugs, potentially causing adverse drug–drug interactions (DDIs). As anti-malarials are generally positively charged at physiological pH, they are likely to interact with human organic cation transporters 1 and 2 (OCT1 and OCT2). These transporters are involved in the uptake of drugs into hepatocytes and proximal tubule cells for subsequent metabolic conversion or elimination. This efflux of cationic drugs from hepatocytes and proximal tubule cells into bile and urine can be mediated by multidrug and toxin extrusion 1 and 2-K (MATE1 and MATE2-K) transporters, respectively.
Here, the interaction of anti-malarials with these transporters was studied in order to predict potential DDIs. Using baculovirus-transduced HEK293 cells transiently expressing human OCT1, OCT2, MATE1 and MATE2K uptake and inhibition was studied by a range of anti-malarials.
Amodiaquine, proguanil, pyrimethamine and quinine were the most potent inhibitors of 4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide (ASP) transport, a known substrate of OCT1/2, resulting in half maximal inhibitory concentrations (IC50) of 11, 13, 1.6, and 3.4 µM, respectively. Only quinine had a drug–drug index higher than the cut-off value of 0.1 for OCT2, therefore, in vivo pharmacokinetic studies focusing on DDIs involving this compound and other OCT2-interacting drugs are warranted. Furthermore, proguanil appeared to be a substrate of OCT1 and OCT2 with affinities of 8.1 and 9.0 µM, respectively. Additionally, MATE1 and MATE2-K were identified as putative transport proteins for proguanil. Finally, its metabolite cycloguanil was also identified as an OCT1, OCT2, MATE1 and MATE2-K substrate.
Anti-malarials can reduce OCT1 and OCT2 transport activity in vitro. Furthermore, proguanil and cycloguanil were found to be substrates of OCT1, OCT2, MATE1 and MATE2-K, highlighting the importance of these transporters in distribution and excretion. As these compounds shares substrate overlap with metformin DDIs can be anticipated during concurrent treatment.
In 2015, there were over 200 million cases of malaria, causing more than 400,000 deaths . To treat uncomplicated malaria infections, the World Health Organization (WHO) recommends the use of artemisinin-based combination therapy (ACT), consisting of an artemisinin-derivative and partner drug that has a longer half-life . The use of a variety of different drugs, like anti-malarials taken during pregnancy or for prophylaxis or Plasmodium vivax relapse prevention, creates a substantial pool of drugs. Considering the geographical overlap with HIV/AIDS and tuberculosis (TB), co-infections could occur. As there are multiple anti-retrovirals (ARV), anti-TB and anti-malarials available for treatment, there is considerable risk for adverse drug–drug interactions (DDIs) if used concomitantly. These DDIs might lead to under- or overexposure of co-administered drugs potentially causing either treatment failure or toxicity. Although DDIs between current co-treatment of HIV and malaria have been predicted to be low , recent studies showed altered anti-malarial plasma concentrations upon ARV treatment [4–6]. Little is known about the potential interaction between anti-malarials and the anti-TB drugs rifampicin and rifabutin , although it has been shown that rifampicin increases the clearance of quinine .
DDIs frequently occur at the level of biotransformation by cytochrome P450 enzymes in the liver , but membrane transport proteins can also be involved . Previously, the potential treatment implications due to possible competition of anti-malarial and antiretroviral DDIs for cellular efflux via ATP binding cassette (ABC) transporters was brought forward . Here, the interaction with organic cation transporters was studied, as anti-malarials are positively charged at physiological pH. Transport proteins belonging to the solute carrier (SLC) family are important for the elimination of drugs, contain members that mainly import cations and have been linked to DDIs. Organic cation transporters (OCT) 1 and OCT2 are cellular uptake transporters belonging to the solute carrier (SLC) family, which are mainly expressed in liver and kidney  and within these organs localize to the basolateral membrane of hepatocyte and proximal tubule cells, respectively [13, 14]. Other important SLCs implicated in the transport of cationic drugs are multidrug and toxin extrusion (MATE) protein 1 and MATE2-K. They are primarily located to the apical side of proximal tubule cells (both) [15, 16] and hepatocytes (MATE1) , where they export drugs into the urine and bile, respectively. As OCT and MATE transporters are important for the cellular uptake and export of drugs, interaction with these transporters could lead to unwanted adverse effects. Therefore, it is important to address interactions of anti-malarials with these transporters, in order to avoid potential drug–drug interactions in future therapy.
The inhibitory potential of eleven anti-malarials (amodiaquine, artemisinin, atovaquone, chloroquine, dihydroartemisinin, lumefantrine, mefloquine, primaquine, proguanil, pyrimethamine, and quinine) on human OCT1 and OCT2 transport activity was studied using HEK293 cells, in which these transporters were overexpressed by baculovirus transduction. Anti-malarials (25–50 μM) that inhibited transport activity by more than 67% were selected for further determination of their half maximal inhibitory concentration (IC50). Furthermore, it was determined which anti-malarials are potential OCT1 or OCT2 substrates and whether MATE1 or MATE2-K could play a role in the cellular efflux of these substrates.
Human embryonic kidney (HEK293) cells transiently expressing (a combination of) human transporters of interest [organic cation transporter 1 or 2 (OCT1; SLC22A1 or OCT2; SLC22A2), multidrug and toxin extrusion protein 1 or 2-K (MATE1; SLC47A1 or MATE2-K; SLC47A2)], or enhanced yellow fluorescent protein (eYFP) were obtained from PharmTox (Nijmegen, The Netherlands).
BioCoat poly-d-lysine coated 24- and 96-wells plates were purchased from Becton–Dickinson B.V. (Breda, The Netherlands). Dulbecco’s Modified Eagle’s Medium (DMEM) + GlutaMAX-I, Hank’s balanced salt solution (HBSS) and 4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide (ASP; ≥ 95% purity) were purchased from Life Technologies Europe B.V. (Bleiswijk, The Netherlands). Fetal bovine serum was purchased from Greiner Bio-One B.V. (Alphen a/d Rijn, The Netherlands). Sodium butyrate, amodiaquine dihydrochloride dehydrate (AQ; analytical standard), artemisinin (ART; 98% purity), atovaquone (ATO; ≥ 98% purity), chloroquine diphosphate (CQ; ≥ 98% purity), dihydroartemisinin (DHA; ≥ 97% purity), lumefantrine (LUM; ≥ 98% purity), mefloquine hydrochloride (MQ; ≥ 98% purity), primaquine diphosphate (PQ; 98% purity), proguanil hydrochloride (PG; ≥ 95% purity), pyrimethamine (PYR; 98.8% purity), quinine (QN; ≥ 98% purity) and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) were purchased from Sigma-Aldrich Chemie B.V. (Zwijndrecht, The Netherlands). Cycloguanil (CG; 95% purity) was purchased from Aurum Pharmatech (Franklin Park, NJ, United States). N-methyl-quinidine (NMQ) was purchased from Solvo Biotechnology (Szeged, Hungary). Bovine serum albumin fraction V (BSA) was purchased from Roche Diagnostics Nederland B.V. (Almere, The Netherlands). The Victor X3 multimode plate reader was purchased from PerkinElmer Nederland B.V. (Groningen, The Netherlands). Bio-Rad protein assay was purchased from Bio-Rad laboratories Inc. (Veenendaal, The Netherlands). The acquity ultra performance liquid chromatography (UPLC) and Xevo TQ-S micro mass spectrometer was purchased from Waters (Milford, MA, USA). Finally, the HSS T3 analytical column and VanGuard HSS T3 pre-column were purchased from Waters (Dublin, Ireland).
HEK293 cell culture and transduction
HEK293 cells were modified to transiently express (a combination of) human OCT1, OCT2, MATE1, MATE2-K, or eYFP. Briefly, cDNA of the respective genes was cloned downstream of a CMV promoter into a baculovirus, of which passage three was used to transduce HEK293 cells. These cells were seeded in poly-d-lysine coated 24- or 96-wells plates and grown in a 37 °C incubator at 5% CO2. Growth was initiated at ~ 25% confluency using 375 or 125 μL cell and complete medium (DMEM + GlutaMAX™-I supplemented with 10% fetal bovine serum) suspension per well, respectively. After 24 h, cells were transduced with 30 µL virus (10 µL virus + 20 µL complete medium in case of 96-wells plates) or 2 × 15 µL virus for cells that required simultaneous expression of two transporters. Finally, 195 µL sodium butyrate (45 µL for 96-wells plates) was added to a final concentration of 2 mM to enhance protein expression .
Cellular transport inhibition assays
AMO (10 mM), ASP (1 mM), CQ (10 mM), PQ (10 mM) and PG (10 mM) were dissolved in MilliQ water. ART (10 mM), ATO (10 mM), DHA (10 mM), LUM (10 mM), MQ (10 mM), NMQ (20 mM), PYR (10 mM), QN (10 mM) were dissolved in DMSO. All compound stocks were stored at − 20 °C. Inhibition of OCT1- or OCT2-mediated ASP uptake by anti-malarials was performed in poly-d-lysine coated 96-wells plates 2 or 3 days following HEK293 cell transduction. In short, cells were washed with 125 µL 37 °C HBSS containing 10 mM HEPES, pH 7.4. Then, a 50 µL mixture of ASP (10 µM) and anti-malarial compound (25, 50 or 100 µM) in HBSS buffer (pH 7.4) was added to each well and incubated for 10 min at 37 °C. ASP transport was stopped by washing with 125 µL ice-cold HBSS-HEPES buffer supplemented with 0.5% BSA. Following a second wash with 125 µL ice-cold HBSS-HEPES buffer, cells were lysed with 125 µL 1 M NaOH and ASP was excited at a wavelength of 485 nm and fluorescence was detected at an emission wavelength of 535 nm using the Victor X3 multimode plate reader. Anti-malarial inhibition of OCT1- or OCT2-mediated ASP uptake was corrected for background signal (eYFP-transduced cells; mock-transduced), normalized to protein content using the Bio-Rad protein assay and represented as relative ASP uptake after fixing solvent controls to 100%. The mean ± standard error of the mean (SEM) of three independent experiments performed in triplicate were plotted in GraphPad Prism version 5.03 (GraphPad Software, Inc., La Jolla, CA, USA) and significantly reduced ASP uptake was determined using a one-way ANOVA with Dunnett’s post test.
Concentration-dependent inhibition was assessed of anti-malarial compounds that inhibited ASP uptake by more than 67% in the initial screens. For each compound, a range of seven concentrations was used to determine the concentration at which ASP uptake was inhibited half maximally (IC50). At least three independent experiments (4 for QN) were performed for each drug in triplicate as described above. Inhibition curves were plotted by nonlinear regression analyses of the data using GraphPad Prism version 5.03. Minimum uptake was set to be greater than 0% and the curve-fitted top within each experiment was adjusted to 100% as follows: each uptake percentage value was multiplied by 100/top in order to let the curve fit start at 100% at the lowest drug concentration. To generate the final dose–response inhibition curve per anti-malarial, percentage of uptake was averaged for each drug concentration per experiment and the resulting mean ± SEM corresponding to three or four independent experiments were plotted.
DDI index calculation
In order to predict whether future pharmacokinetic studies are recommended to study transporter inhibition in vivo, DDI indices were calculated by using the formula DDI index = fraction unbound * Cmax/IC50 with a cut-off value of 0.1 . As Cmax the (geometric) mean or median maximum plasma concentrations obtained from previous in vivo pharmacokinetic studies after therapeutic dosing was used.
Cellular import and export assays
HEK293 cells were seeded in 24-wells poly-d-lysine coated plates and transduced the subsequent day with OCT1 or OCT2 as described above. Three days following transduction, OCT1- or OCT2-mediated uptake of ten anti-malarials (AMO, ART, ATO, CQ, DHA, LUM, MQ, PQ, PG, and QN) was performed. NMQ served as a positive substrate for both OCT1 and OCT2 import . In short, cells were washed with 400 µL 37 °C HBSS-HEPES buffer followed by adding 150 µL HBSS buffer with 10 µM anti-malarial or NMQ to each well. After incubation for 15 min at 37 °C, import was stopped by washing with 400 µL ice-cold HBSS-HEPES buffer supplemented with 0.5% BSA. Following a second wash with 400 µL ice-cold HBSS-HEPES buffer, cells were lysed with 200 µL 50% (v/v) MeOH and 0.1% (v/v) formic acid (HCOOH) in water and samples were sent for quantification by mass spectrometry analysis (see “LC–MS/MS quantification of anti-malarials” section). Anti-malarial import mediated by OCT1 or OCT2 was performed in two independent experiments in triplicate per drug and normalized to background (mock-transduced cells). Percentage of anti-malarial uptake (compared to background control) was plotted as mean (6 values) ± SEM in GraphPad Prism version 5.03 and drugs with at least a twofold increase versus background were selected for further analysis.
The affinity (KM) and maximum transport rate (Vmax) for OCT1 and OCT2 of PG were determined by analysing concentration-dependent uptake data from three independent experiments. The experimental setup was similar to the cellular import assay, except that a range of four concentrations (2.0, 3.9, 7.8 and 16 µM) and an incubation time of 1 min was used to determine the KM of proguanil. The Michaelis–Menten curve was plotted as mean ± SEM in GraphPad version 5.03 after fixing the Vmax of each individual experiment to 100% and subtracting mock-transduced background for each concentration used.
Import and export of PG and cycloguanil (CG) was assessed by single and double transduced HEK293 cells. In short, HEK293 cells seeded in 24-wells plates as described, were transduced separately with eYFP, OCT1, OCT2, MATE1 or MATE2-K, or with combinations of these viruses. Following the same procedure as for the cellular import assay described above, the import of 100 µM PG and CG was measured after 5 min incubation and data was plotted as mean pmol/mg/min ± SEM. For export (following OCT1 uptake) of 1 µM PG after 1 min of transport at pH 7.4, percentage of remaining cellular PG (compared to background) was plotted as mean ± SEM in GraphPad version 5.03. Significant reduction in uptake (i.e. export by MATEs) was determined using ln transformation and a one-way repeated measures ANOVA with Dunnet’s post test.
Liquid chromatography–tandem mass spectrometry (LC–MS/MS) quantification of anti-malarials
Mass fragments of the most abundant ions for the detection of anti-malarials by LC–MS/MS
Precursor ion (m/z)
Product ion (m/z)
Inhibition of OCT1- and OCT2-mediated ASP transport by anti-malarials
OCT1- and OCT2-mediated proguanil and cycloguanil uptake
Next, the transport kinetics of PG uptake by OCT1 and OCT2 (eYFP-transduced cells served as background control) were studied. Concentration-dependent uptake of PG was measured during 1 min of incubation at 37 °C and its affinity (KM) and maximum transport rate (Vmax) were determined. Uptake of PG by OCT1 was characterized by a KM of 8.1 ± 1.6 µM and Vmax of 1840 ± 510 pmol/mg protein/min. PG affinity for OCT2 was similar with a KM of 9.0 ± 1.1 µM and Vmax of 4440 ± 1500 pmol/mg protein/min (Fig. 2c, d).
As PG is metabolized in the liver to its active metabolite CG by CYP2C19 , CG transport by OCT1 or OCT2 was investigated. Uptake studies of CG were performed similarly as with the previous anti-malarials, with a 5 min incubation time at 37 °C. This resulted in significant uptake by OCT1 and OCT2 into HEK293 cells (Fig. 2e).
MATE1 and MATE2-K-mediated proguanil and cycloguanil transport
To study PG export capacity of MATE1 and MATE2-K, HEK293 cells were co-transduced with eYFP (mock) and OCT1, OCT1 and MATE1, or OCT1 and MATE2-K. Uptake was represented as percentage of eYFP control cells. Incubation of 1 µM PG for 1 min resulted in eightfold uptake by OCT1 (850 ± 60% of control) (Fig. 3b). This uptake was similar in cells expressing OCT1 and MATE1 (780 ± 70% of control) simultaneously. However, uptake was significantly reduced in cells expressing OCT1 and MATE2-K (470 ± 80% of control, p < 0.01), indicating that approximately 50% of PG was exported by MATE2-K as compared to eYFP/OCT1 transduced cells.
Finally, CG was analysed as a potential MATE1 and MATE2-K substrate by transfecting HEK293 cells with these transporters. Incubation of 100 µM CG for 5 min resulted in significant uptake by MATE1 (40 ± 9 pmol/mg/min) and MATE2-K (56 ± 15 pmol/mg/min) compared to control cells (11.8 ± 0.9 pmol/mg/min) (Fig. 3c). This highlights the involvement of MATE1 and MATE2-K in excretion of PG and its metabolite CG.
In this study, the focus was on the interaction of anti-malarial drugs with the organic cation transporters OCT1, OCT2, MATE1 and MATE2-K. In vitro, OCT1 activity was not affected by any of the tested anti-malarials, while OCT2 was inhibited in the low micromolar range by AQ, PG, PYR and QN. These compounds all share structural features with other OCT2 inhibitors as predicted previously .
Inhibition of OCT2 by AQ and PG has not been reported previously. The calculated DDI indices of both drugs were below 0.1, indicating that clinically relevant DDIs related to OCT1 and OCT2 transport are unlikely to occur, but should not be fully excluded as local concentrations at the site of the transporter might be higher compared to systemic levels. Although it has been shown that co-administration of efavirenz (EFV), lopinavir (LPV)/ritonavir (RTV) or atazanavir/RTV with ATO/PG cause a reduction in the AUC of both anti-malarials , the decrease in PG level was attributed to induction of CYP2C19 by EFV and LPV/RTV [23, 24]. In contrast, EFV has been shown to increase Cmax levels of PG by 47%, most likely caused by inhibition instead of induction of CYP2C19 metabolism, which was supported by a reduction in cycloguanil (CG) levels . Another explanation for an increase in PG plasma concentration might be that EFV was also shown to be an inhibitor (absolute IC50 of 22 μM) of OCT1  and it was demonstrated that PG is a substrate of OCT1. However, although maximum plasma concentrations of EFV reach 13 μM , only about 0.22% is unbound (0.03 μM) , resulting in a DDI index for OCT1 well below 0.1, which makes an increase in the Cmax of PG unlikely. The AUC of EFV has been shown to increase in two subjects in a pharmacokinetic study upon simultaneous AQ/artesunate treatment, resulting in increased hepatic transaminase levels . Although we demonstrated that AQ inhibits OCT2, the calculated DDI index is very low. Hence, boosted EFV levels involving this transporter (and assuming that EFV is an OCT2 substrate) are highly unlikely.
PYR was shown to be the strongest inhibitor of OCT2 activity with an IC50 of 1.6 µM. Previously, PYR has been shown to reduce OCT2 activity by 60% at a concentration of 50 µM . This is a substantial difference with the presented findings, but could be explained by differences in cell type (HEK293 vs. HeLa) and substrate (concentration) [ASP vs. metformin (MET)] used. Results from another group, studying inhibition of MET elimination by PYR , were more in accordance with ours. Using HEK293 cells stably expressing human OCT2, a Ki value of 10 µM PYR for OCT2-mediated MET uptake was found. Although PYR was capable of increasing MET AUC at therapeutic dose, this effect was attributed to inhibition of MATE1 and MATE2-K, as their Ki values were over 100-fold lower than the Ki value for OCT2 inhibition .
In a previous study with stably transfected OCT1 and OCT2 HEK293 cells, inhibition of N-[methyl-3H]4-phenylpyridinium ([3H]MPP+) uptake by QN resulted in IC50 concentrations of 13 and 23 µM for OCT1 and OCT2, respectively . While QN was found to be more potent at inhibiting OCT1 , in this study QN was a more potent inhibitor of OCT2, which might be explained by a different choice of substrate. The presented results more closely resemble two other studies, that also used ASP as a substrate, and found that 20 µM QN inhibited OCT2 by 72%  and 100 µM QN inhibited OCT1 by 60% . In the current study, the highest reported DDI index was 1.1 for QN. While DDIs for QN have been described, and a potential role at the transport level by P-glycoprotein/ABCB1 inhibition was studied previously , until now clinically relevant interactions caused by QN inhibition of OCT2 have not been reported. A pharmacokinetic study showed that concurrent administration with RTV resulted in a modest increase of Cmax and AUC of QN . Since RTV is not an OCT2 substrate , a transporter interaction with QN is unlikely. Inhibition of CYP2D6 by QN was speculated to cause this effect. In addition, simultaneous RTV and QN administration resulted in an approximately fourfold increase in Cmax and AUC of QN, which might be due to CYP3A4 interactions .
The DDI indices reported here should be interpreted with caution, as multiple factors may influence this value. Firstly, individual peak plasma concentrations in a different population may be substantially higher than the (geometric) mean or median shown in Table 2. Furthermore, the unbound fraction of a drug may alter depending on, e.g. plasma pH , pregnancy  and disease status. Indeed, in the case of QN treatment, increased intensity of malaria infection correlated with more plasma protein binding (lower unbound fraction) of QN [36, 37]. Still, as QN blood concentration rises with severity of disease , unbound QN concentrations may remain at a similar level due to a higher plasma protein binding .
In addition, when MATE1 and MATE2-K were transduced in HEK293 cells this resulted in a small significant uptake of PG by MATE1. When CG was used as potential substrate, uptake by MATE1 and MATE2-K was clearly present. Furthermore, in order to study the ability of MATE1 and MATE2-K to efflux PG, co-transduction studies were performed. When MATE1 and MATE2-K were co-transduced with OCT1, only MATE2-K reduced the intracellular PG concentration to 56% of its initial value indicating export of PG by this transporter. Thus, both CG and PG are most likely substrates of MATE1 and MATE2-K, who secrete these compounds from the proximal tubule into urine. Interestingly, PG shows structural similarity to MET (both contain guanidine fragments), a known MATE1 , MATE2-K , OCT1 , and OCT2  substrate. It has been shown that polymorphisms in OCT1 can cause reduced liver uptake of MET , hence, these variants might also result in reduced hepatic PG uptake leading to less CG conversion. Additionally, as MET is the first-line drug of choice to treat type 2 diabetes (DMII), adverse drug interactions with PG may be anticipated, e.g. when the latter compound is used as prophylactic drug in travelers with DMII.
In the present study, the interaction of parent compounds with transport proteins was investigated. As part of these anti-malarials undergo biotransformation in the body, their metabolites might also influence transport activity. Therefore, future research should focus on these products as they might increase the DDI potential of their parent compound or have different targets that may cause separate DDIs.
In conclusion, anti-malarials can reduce OCT1 and OCT2 transport activity in vitro. Only QN inhibited OCT2 at a therapeutic relevant dose with a DDI index above the 0.1 cut-off value, warranting in vivo pharmacokinetic studies. However, many factors influence this value and, therefore, individual cases of DDI with other tested compounds cannot be excluded. While anti-malarials and anti-retrovirals are often used concomitantly and may cause adverse DDIs, they most likely are not resulting from interactions with transporters described here due to differential substrate specificity for anti-retrovirals or low DDI indices. Furthermore, CG and PG were found to be substrates of OCT1, OCT2, MATE1 and MATE2-K, highlighting the importance of these transporters in CG and PG distribution and excretion. As PG shares substrate overlap with MET for OCT1, OCT2, MATE1 and MATE2-K, DDIs can be anticipated during concurrent treatment.
MvdV, RWS, FGMR, and JBK conceived the study. All authors participated in the design of the study. MvdV, JJMWvdH, SRR, EGEH designed and performed the transport assays. AB performed and analysed the LC–MS/MS assays. MvdV wrote the first draft of the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Availability of data and materials
Consent for publication
Ethics approval and consent to participate
Maarten van der Velden was supported by a Radboud University Medical Center personal grant.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- WHO. Malaria fact sheet no. 94. Geneva: World Health Organization; 2015.Google Scholar
- WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.Google Scholar
- Khoo S, Back D, Winstanley P. The potential for interactions between antimalarial and antiretroviral drugs. AIDS. 2005;19:995–1005.View ArticlePubMedGoogle Scholar
- van Luin M, Van der Ende ME, Richter C, Visser M, Faraj D, Van der Ven A, et al. Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. AIDS. 2010;24:1223–6.View ArticlePubMedGoogle Scholar
- Soyinka JO, Onyeji CO. Alteration of pharmacokinetics of proguanil in healthy volunteers following concurrent administration of efavirenz. Eur J Pharm Sci. 2010;39:213–8.View ArticlePubMedGoogle Scholar
- German P, Parikh S, Lawrence J, Dorsey G, Rosenthal PJ, Havlir D, et al. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr. 2009;51:424–9.View ArticlePubMedGoogle Scholar
- Sousa M, Pozniak A, Boffito M. Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs. J Antimicrob Chemother. 2008;62:872–8.View ArticlePubMedGoogle Scholar
- Wanwimolruk S, Kang W, Coville PF, Viriyayudhakorn S, Thitiarchakul S. Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man. Br J Clin Pharmacol. 1995;40:87–91.View ArticlePubMedPubMed CentralGoogle Scholar
- Bibi Z. Role of cytochrome P450 in drug interactions. Nutr Metab (Lond). 2008;5:27.View ArticleGoogle Scholar
- Muller F, Fromm MF. Transporter-mediated drug–drug interactions. Pharmacogenomics. 2011;12:1017–37.View ArticlePubMedGoogle Scholar
- Rijpma SR, van den Heuvel JJ, van der Velden M, Sauerwein RW, Russel FG, Koenderink JB. Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity. Malar J. 2014;13:359.View ArticlePubMedPubMed CentralGoogle Scholar
- Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, et al. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997;16:871–81.View ArticlePubMedGoogle Scholar
- Nies AT, Herrmann E, Brom M, Keppler D. Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). Naunyn Schmiedebergs Arch Pharmacol. 2008;376:449–61.View ArticlePubMedGoogle Scholar
- Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, et al. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol. 2002;13:866–74.PubMedGoogle Scholar
- Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci USA. 2005;102:17923–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T, et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol. 2006;17:2127–35.View ArticlePubMedGoogle Scholar
- Gorman CM, Howard BH, Reeves R. Expression of recombinant plasmids in mammalian cells is enhanced by sodium butyrate. Nucleic Acids Res. 1983;11:7631–48.View ArticlePubMedPubMed CentralGoogle Scholar
- International-Transporter-Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215–36.View ArticleGoogle Scholar
- van Montfoort JE, Muller M, Groothuis GM, Meijer DK, Koepsell H, Meier PJ. Comparison of “type I” and “type II” organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001;298:110–5.PubMedGoogle Scholar
- Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, et al. Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J Med Chem. 2008;51:5932–42.View ArticlePubMedGoogle Scholar
- Kido Y, Matsson P, Giacomini KM. Profiling of a prescription drug library for potential renal drug–drug interactions mediated by the organic cation transporter 2. J Med Chem. 2011;54:4548–58.View ArticlePubMedPubMed CentralGoogle Scholar
- Funck-Brentano C, Becquemont L, Lenevu A, Roux A, Jaillon P, Beaune P. Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. J Pharmacol Exp Ther. 1997;280:730–8.PubMedGoogle Scholar
- Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr. 2006;42:52–60.PubMedGoogle Scholar
- Damle B, LaBadie R, Crownover P, Glue P. Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. Br J Clin Pharmacol. 2008;65:523–30.View ArticlePubMedPubMed CentralGoogle Scholar
- Moss DM, Liptrott NJ, Siccardi M, Owen A. Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter. Front Pharmacol. 2015;6:78.PubMedPubMed CentralGoogle Scholar
- Villani P, Regazzi MB, Castelli F, Viale P, Torti C, Seminari E, Maserati R. Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. Br J Clin Pharmacol. 1999;48:712–5.View ArticlePubMedPubMed CentralGoogle Scholar
- Avery LB, Sacktor N, McArthur JC, Hendrix CW. Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration. Antimicrob Agents Chemother. 2013;57:1409–14.View ArticlePubMedPubMed CentralGoogle Scholar
- German P, Greenhouse B, Coates C, Dorsey G, Rosenthal PJ, Charlebois E, et al. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin Infect Dis. 2007;44:889–91.View ArticlePubMedGoogle Scholar
- Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010;298:F997–1005.View ArticlePubMedGoogle Scholar
- Kusuhara H, Ito S, Kumagai Y, Jiang M, Shiroshita T, Moriyama Y, et al. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther. 2011;89:837–44.View ArticlePubMedGoogle Scholar
- Muller J, Lips KS, Metzner L, Neubert RH, Koepsell H, Brandsch M. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 2005;70:1851–60.View ArticlePubMedGoogle Scholar
- Soyinka JO, Onyeji CO, Omoruyi SI, Owolabi AR, Sarma PV, Cook JM. Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. Br J Clin Pharmacol. 2010;69:262–70.View ArticlePubMedPubMed CentralGoogle Scholar
- Jung N, Lehmann C, Rubbert A, Knispel M, Hartmann P, van Lunzen J, et al. Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos. 2008;36:1616–23.View ArticlePubMedGoogle Scholar
- Hinderling PH, Hartmann D. The pH dependency of the binding of drugs to plasma proteins in man. Ther Drug Monit. 2005;27:71–85.View ArticlePubMedGoogle Scholar
- Perucca E, Crema A. Plasma protein binding of drugs in pregnancy. Clin Pharmacokinet. 1982;7:336–52.View ArticlePubMedGoogle Scholar
- Wanwimolruk S, Denton JR. Plasma protein binding of quinine: binding to human serum albumin, alpha 1-acid glycoprotein and plasma from patients with malaria. J Pharm Pharmacol. 1992;44:806–11.View ArticlePubMedGoogle Scholar
- Silamut K, Molunto P, Ho M, Davis TM, White NJ. Alpha 1-acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria. Br J Clin Pharmacol. 1991;32:311–5.View ArticlePubMedPubMed CentralGoogle Scholar
- White NJ, Looareesuwan S, Warrell DA, Warrell MJ, Bunnag D, Harinasuta T. Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. Am J Med. 1982;73:564–72.View ArticlePubMedGoogle Scholar
- GlaxoSmithKline Inc. Malarone. GSK Product Monograph. Research Triangle Park, NC, GSK. 2004.Google Scholar
- Somogyi AA, Reinhard HA, Bochner F. Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism. Br J Clin Pharmacol. 1996;41:175–9.View ArticlePubMedGoogle Scholar
- Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, Inui K. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007;74:359–71.View ArticlePubMedGoogle Scholar
- Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, Inui K. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005;20:379–86.View ArticlePubMedGoogle Scholar
- Kimura N, Okuda M, Inui K. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm Res. 2005;22:255–9.View ArticlePubMedGoogle Scholar
- Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Investig. 2007;117:1422–31.View ArticlePubMedPubMed CentralGoogle Scholar
- Mwesigwa J, Parikh S, McGee B, German P, Drysdale T, Kalyango JN, et al. Pharmacokinetics of artemether–lumefantrine and artesunate–amodiaquine in children in Kampala, Uganda. Antimicrob Agents Chemother. 2010;54:52–9.View ArticlePubMedGoogle Scholar
- Giao PT, de Vries PJ. Pharmacokinetic interactions of antimalarial agents. Clin Pharmacokinet. 2001;40:343–73.View ArticlePubMedGoogle Scholar
- Sabchareon A, Attanath P, Phanuaksook P, Chanthavanich P, Poonpanich Y, Mookmanee D, et al. Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg. 1998;92:201–6.View ArticlePubMedGoogle Scholar
- Barnes KI, Little F, Smith PJ, Evans A, Watkins WM, White NJ. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin Pharmacol Ther. 2006;80:582–96.View ArticlePubMedGoogle Scholar
- Rudy AC, Poynor WJ. Binding of pyrimethamine to human plasma proteins and erythrocytes. Pharm Res. 1990;7:1055–60.View ArticlePubMedGoogle Scholar
- Pukrittayakamee S, Wanwimolruk S, Stepniewska K, Jantra A, Huyakorn S, Looareesuwan S, White NJ. Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated Falciparum malaria. Antimicrob Agents Chemother. 2003;47:3458–63.View ArticlePubMedPubMed CentralGoogle Scholar